Thromboembolism direct thrombin inhibitors

Agnelli G, Sonaglia F, Becattini C. Direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery. Curr Pharm Des. 2005 11 3885-3891. 

Eriksson Bl, Dahl OE. Prevention of venous thromboembolism following orthopaedic surgery clinical potential of direct thrombin inhibitors. Drugs 2004 64 577-595. 

Eriksson Bl, Arfwidsson AC, Frison L, et al. A dose-ranging study ofthe oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement METHRO I, MEIagatran for THRombin inhibition in Orthopaedic surgery. Thromb Haemost 2002 87 231-237. 

Agnelli G, Clinical potential of oral direct thrombin inhibitors in the prevention and treatment of venous thromboembolism. Drugs 2004 64(suppl I ) 47—52. 

Eriksson Bl, Agnelli G, Cohen AT, et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement the EXPRESS study. J Thromb Haemost 2003 1 2490-2496. 

Schulman S, Wahlander K, Lundstrom T et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran, N Engl J Med 2003 349 1713-1721. 

Eriksson Bl, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement the BISTRO II randomized trial. J Thromb Haemost 2005 3 103-1 I I. 

Colwell CW Jr, Berkowitz SD, Lieberman JR, et al. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am 2005 87 2169-2177. 

---